美国社区超重与肥胖人群中脂肪性肝病、进展性纤维化及肝硬化的患病率
该研究为横断面分析,前瞻性纳入美国南加州基层与社区40-75岁超重或肥胖成人539例,用MRI质子密度脂肪分数≥5%定义脂肪性肝病(SLD),并按新命名分为MASLD、MetALD和ALD,用磁共振弹性成像(MRE)≥3.63 kPa和≥4.67 kPa分别定义进展性纤维化和肝硬化。结果显示SLD、进展性纤维化和肝硬化患病率分别为75%、10.8%和4.5%;MASLD、MetALD和ALD分别为67.3%、4.8%和2.6%;各亚类间进展性纤维化和肝硬化患病率无差异。作者认为可考虑对超重/肥胖成人进行进展性纤维化系统性筛查。
要点
- 社区超重/肥胖成人中SLD患病率为75%,MASLD最常见(67.3%)。
- 进展性纤维化和肝硬化患病率分别为10.8%和4.5%。
- 作者认为可考虑对超重/肥胖成人筛查进展性纤维化。
核心结论
- 在社区居住的超重和肥胖成人中,采用先进MRI方法测得肝硬化患病率为4.5%。
- SLD最常见亚类为MASLD,占67%,MetALD和ALD较少见。
- 作者认为可考虑对超重/肥胖成人进行进展性纤维化的系统性筛查。
研究设计与样本
- 该研究为横断面分析,前瞻性纳入美国南加州基层和社区环境中40-75岁的超重或肥胖成人。
- 共纳入539名参与者,平均(±SD)年龄51.5(±13.1)岁,平均BMI 32.6(±6.2)kg/m2。
- SLD定义为MRI质子密度脂肪分数≥5%,并按AASLD-EASL-ALEH新命名分为MASLD、MetALD和ALD。
- 进展性纤维化定义为MRE≥3.63 kPa,肝硬化定义为MRE≥4.67 kPa。
主要发现
- SLD、进展性纤维化和肝硬化的患病率分别为75%、10.8%和4.5%。
- MASLD、MetALD和ALD的患病率分别为67.3%、4.8%和2.6%。
- 各SLD亚类间进展性纤维化和肝硬化的患病率无差异。
关键数值与推荐
- SLD诊断阈值:MRI质子密度脂肪分数≥5%。
- 进展性纤维化诊断阈值:MRE≥3.63 kPa。
- 肝硬化诊断阈值:MRE≥4.67 kPa。
- SLD亚类分类依据AASLD-EASL-ALEH新命名指南。
临床怎么用
- 作者认为可考虑对超重/肥胖成人进行进展性纤维化的系统性筛查。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are limited prospective data among overweight and obese individuals on the prevalence of advanced fibrosis, and cirrhosis using advanced MRI-based methods in the USA. The aim of this study was to fill that gap in knowledge by prospectively determining the MRI-based prevalence of steatotic liver disease (SLD) and its subcategories, advanced fibrosis and cirrhosis among overweight and obese individuals residing in the USA. METHODS: This is a cross-sectional analysis of prospectively enrolled overweight or obese adults aged 40-75 years from primary care and community-based settings in Southern California. Participants were classified as having SLD if MRI proton density fat fraction ≥5%, and subclassified as metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-associated liver disease (MetALD) and alcohol-related liver disease (ALD) consistently with the new nomenclature guidance per AASLD-EASL-ALEH. Advanced fibrosis and cirrhosis were defined as magnetic resonance elastography (MRE) ≥3.63 kPa and MRE ≥4.67 kPa, respectively. RESULTS: The cohort included 539 participants with mean (±SD) age of 51.5 (±13.1) years and body mass index of 32.6 (±6.2) kg/m2, respectively. The prevalence of SLD, advanced fibrosis and cirrhosis was 75%, 10.8% and 4.5%, respectively. The prevalence of MASLD, MetALD and ALD was 67.3%, 4.8% and 2.6%, respectively. There was no difference in prevalence of advanced fibrosis and cirrhosis among subcategories. CONCLUSIONS: Using advanced MRI methods among community-dwelling overweight and obese adults, the prevalence of cirrhosis was 4.5%. Most common SLD subcategory was MASLD with 67% of individuals, whereas MetALD and ALD were less common. Systematic screening for advanced fibrosis among overweight/obese adults may be considered.
引用
- Yang AH, Tincopa MA, Tavaglione F, et al. Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA. Gut. 2024. PMID: 39117370. doi:10.1136/gutjnl-2024-332917
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。